SRZN Surrozen, Inc.

NASDAQ

$29.54

Surrozen, Inc. (SRZN) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $1.32 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +18.9% since its last earnings release on August 6, 2026.

Surrozen Beat Consensus Estimates

Thursday, August 6, 2026 · 4:05 PM ET

3rd Quarter, Sep 2026

Thursday · 4:05 PM ET

Earnings Whisper

-

vs ($1.32)

Volatility

Enter your expectations below to reveal the current volatility.

Trend Analysis

Expectation

Earnings

Price action

Signals

Score

Sentiment

Grade

Life Cycle

Call Analysis

Earnings-AVWAP $21.87

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Surrozen, Inc.

Surrozen is a clinical stage biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.